maintrac® enables the gentle detection of living circulating tumor cells in the blood of patients with cancer and supports monitoring of disease progression as well as individualized therapy adjustment.
Monitoring changes in the number of living circulating tumor cells shows the effectiveness of the therapy and correlates with the further course of the cancer.
With the maintrac® drug sensitivity test, it can be examined how your circulating tumor cells respond to various chemotherapeutic agents – for a more targeted treatment.
maintrac® examines therapy-relevant characteristics of your tumor cells and helps to identify which maintenance therapy may be useful for you – individual and targeted.
With stemtrac®, especially aggressive tumor stem cells in the blood can be detected – a possible indication of metastasis and an increased risk of relapse.
maintrac® cell count enables the precise detection of viable circulating tumor cells (CETCs / CTCs) in the blood. The method allows for the quantitative tracking of these cells over time and provides insights into disease progression, therapy response, and also serves to monitor Minimal Residual Disease (MRD). It is suitable for monitoring disease course and supporting therapy decisions in cancer patients.
maintrac® drug sensitivity testing evaluates in vitro the effect of various substances directly on viable circulating tumor cells. This allows identification of the most effective individual therapy and enables a personalized treatment tailored specifically to each patient.
maintrac® analysis of therapy-relevant charakteristics enables the identification of specific markers on circulating tumor cells that provide insights into the response to various therapies. This supports personalized therapy planning and helps select the most effective treatment options for the patient.
stemtrac® tumorspheres is a functional test for the detection of circulating cancer stem cells. The number of tumorspheres is associated with the aggressiveness of the primary tumor and the risk of disease progression. The test helps assess the metastatic potential of the tumor and supports personalized oncology treatment.
The timing of the blood draw is crucial for the accuracy of the results. Only precise sample collection at the optimal time can ensure reliable and meaningful results.
Find out here the most recent press releases about maintrac® cancer diagnostics.
On this page we will keep you updated about upcoming events which we are participating.
On this page, you can find out about how to receive the lab request form for maintrac®; you will also be provided with information on how the blood samples should be send.
You can download our current information documents here. There you will learn about the applications of maintrac®.
Obtain an overview Verschaffen Sie sich einen Überblick zu den wichtigsten Studien und Publikationen der letzten Jahre. Bei Fragen zur Literatur wenden Sie sich gerne direkt an uns.
On this page, you can find some selected information materials for download.
In this brochure, you will find information on the areas of application of maintrac®. You will also learn about the advantages that maintrac® diagnostics offers patients.
In this flyer you will learn details about maintrac® Cell Counting. You will learn when maintrac® Cell Counting can be used and how the cell count trajectory can be interpreted.
maintrac® Therapeutic Substance Testing indicates the efficacy of cytotoxic substances on living circulating tumor cells even before the start of therapy. It is also shown in which situations it can be performed.
Testing of maintrac® Therapy Relevant Tumor Cell Characteristics can provide additional information about the response to potential targeted therapy. Among other things, you will find a list of all biomarkers that we test.
stemtrac® Tumorspheres identifies the circulating cancer stem cells. The tumor spheres can grow from these in vitro. The number of tumor spheres provides an indication of the aggressiveness of the tumor and the risk of metastasis.